Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Sees Positive Top-Line Results in Abrocitinib Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2019 | 07:16am EDT

By Chris Wack

Pfizer Inc. (PFE) said Wednesday that it saw positive top-line results from a Phase 3 pivotal study for its investigational oral Janus kinase 1 inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.

The pharmaceutical company said in a release that top-line results showed that by week 12, the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was statistically significantly higher than placebo.

Pfizer said the results demonstrate response to treatment for a statistically significant number of patients during the first two to four weeks following the first dose.

The company said that safety results showed that both doses of abrocitinib were well-tolerated and there were no unexpected safety events. The discontinuation rates due to an adverse event were low in each treatment arm compared to placebo.

Write to Chris Wack at chris.wack@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
07:01aTHE PFIZER FOUNDATION : Invests in 20 Organizations Tackling Infectious Diseases..
BU
08/19Who is next in big pharma's merger spree?
RE
08/16FITCH RTGS : US Pharma M&A, Portfolio Reshaping, R&D Offset Growth Risk
AQ
08/15Pfizer Recalls Two Lots of Relpax Over Possible Contamination
DJ
08/14PFIZER : Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® (eletriptan ..
PU
08/14PFIZER : Oncolytics Biotech Reports 2019 Second Quarter Financial Results and Op..
AQ
08/14Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt
RE
08/13PFIZER : City moves who's switching jobs
AQ
08/12Health Care Down, But Losses Limited by Lack of Cyclical Exposure -- Health C..
DJ
08/09PFIZER : Description Post-Effective Amendment to an S-8 filing
PU
More news
Financials (USD)
Sales 2019 51 749 M
EBIT 2019 18 934 M
Net income 2019 11 493 M
Debt 2019 30 778 M
Yield 2019 4,14%
P/E ratio 2019 15,0x
P/E ratio 2020 14,7x
EV / Sales2019 4,29x
EV / Sales2020 4,53x
Capitalization 191 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 43,77  $
Last Close Price 34,61  $
Spread / Highest target 58,9%
Spread / Average Target 26,5%
Spread / Lowest Target -4,65%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-19.40%194 582
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%239 457
MERCK AND COMPANY12.80%220 679
NOVARTIS17.81%205 341
AMGEN5.82%123 538